The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025 takes place in Vösendorf, Austria on 24-25 November. The 5th anniversary edition of AUTOMA+ gathers leading innovators and IT professionals to discuss the directions of the advanced industry shift and celebrate this milestone together.
The 2-day agenda includes topics:
Ethical and human-centric AI;
Smart manufacturing techniques (digital…
BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships.
This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Animal Health, and Biosimilars. Check out our full report below:
Novartis Reports Topline P-III (NEPTUNUS-1 & 2) Trials Finding on Ianalumab to Treat Active Sjögren’s Disease
Read More: Novartis
Stoke Therapeutics and Biogen Report First Patient Dosing in P-III (EMPEROR)…
Aesthetic and beauty industry, underplayed by cosmeceuticals, shapes a soaring market worth $312.33B. Cosmeceuticals are known for their medical benefits beyond cosmetics and typically come in the forms of topical creams, serums, and lotions
Let’s unearth the secrets of cosmeceuticals like never before through engaging articles, illustrative infographics, regulatory updates, and much more [ps_download_button]
The…
We are now halfway through 2025, and it’s not too late to highlight the practices and trends that are shaping and will continue to shape the biopharma landscape this year. In 2024, we navigated the 4 biopharma trends that exerted vehement force in the industry and shaped the course of healthcare practices. Last year, the…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of July 2025
The US FDA has approved a total of 6 new drugs, including 5 new molecular entities and 1 biologic, leading to the treatment of patients and advances in the pharmaceutical industry
The major highlighted drug was Regeneron’s Lynozyfic, securing…
EVERYONE has a heroic story to tell, their own legend to fulfill and HLTH is forging ahead into new realms of possibilities, gathering 12,000+ influential leaders, executives and visionaries who are passionately creating the next generation of healthcare. At HLTH you can foster meaningful connections, gain insights on cutting-edge trends, enhance your professional journey, or…
Shots:
PharmaShots speaks with Thomas Chalberg, Founder and CEO of Genascence Corporation, and Annahita Keravala, Founder and CSO of Genascence Corporation
Thomas and Annahita speak eloquently about Genascence's current lead program, GNSC-001, for osteoarthritis of the knee, and shed light on the unmet medical needs in the disease
The duo highlighted the safety and tolerability…
Shots:
Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025
Robert Iannone, CMO, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared four-year follow-up data from an ongoing P-II trial of Ziihera in combination with CT for…
This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, Biotech, M&A and Biosimilars. Check out our full report below:
Roche Reports P-III (Portal) Trial Data on Susvimo for Neovascular Age-Related Macular Degeneration (nAMD)
Read More: Roche
Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma
Read…

